Oct 22, 2026 · 44 min
Supreme Court ruling tests transgender rights as Tesla eyes SpaceX merger
SCOTUS Hands Trump Loss on Transgender Rights & Tesla/SpaceX Merger
The episode connects a consequential transgender-rights dispute with questions about presidential control of regulators and the legal risks facing a Tesla–SpaceX combination.
- 1The Supreme Court left hormone treatments and related accommodations in place for transgender federal inmates while broader cases loom.
- 2A new SEC quorum rule could let one commissioner act alone, raising questions about agency authority, enforcement, and presidential influence.
- 3A Tesla–SpaceX merger would face Texas corporate-law disputes, shareholder challenges, antitrust review, and national-security scrutiny.
Don't miss
Eric Talley maps how a Tesla–SpaceX merger could encounter simultaneous shareholder, Texas corporate-law, antitrust, and national-security challenges.
The brief
The Supreme Court refused to halt hormone treatments and related accommodations for transgender federal inmates, while leaving broader questions for future cases.
Suzanne Goldberg explains the narrow emergency-docket ruling, the Bureau of Prisons’ longstanding policy, and the administration’s arguments about medical evidence and inmate safety.
Eric Talley examines an SEC rule allowing a single commissioner to act when the agency is short-staffed or a member is recused, potentially concentrating authority.
The proposed Tesla–SpaceX merger raises questions about independent board committees, Elon Musk’s control, shareholder approval, fiduciary duties, and Texas’s new business court.
Talley outlines the merger’s remaining hurdles: corporate litigation, antitrust review under the Trump administration, and national-security scrutiny through CFIUS.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.